Horan Capital Advisors LLC. raised its holdings in Celgene Corporation (NASDAQ:CELG) by 3.2% in the second quarter, according to the company in its most recent disclosure with the SEC. The firm owned 28,009 shares of the biopharmaceutical company’s stock after acquiring an additional 881 shares during the quarter. Celgene Corporation accounts for about 2.5% of Horan Capital Advisors LLC.’s holdings, making the stock its 6th biggest position. Horan Capital Advisors LLC.’s holdings in Celgene Corporation were worth $3,638,000 as of its most recent filing with the SEC.

Other institutional investors have also added to or reduced their stakes in the company. Neuberger Berman Group LLC lifted its holdings in Celgene Corporation by 4.0% in the first quarter. Neuberger Berman Group LLC now owns 1,844,837 shares of the biopharmaceutical company’s stock valued at $229,553,000 after acquiring an additional 71,729 shares during the period. Lincoln Capital Corp lifted its holdings in Celgene Corporation by 0.6% in the second quarter. Lincoln Capital Corp now owns 30,580 shares of the biopharmaceutical company’s stock valued at $3,971,000 after acquiring an additional 185 shares during the period. Grisanti Capital Management LLC acquired a new stake in Celgene Corporation in the second quarter valued at $3,616,000. Swiss National Bank lifted its holdings in Celgene Corporation by 27.2% in the first quarter. Swiss National Bank now owns 2,746,896 shares of the biopharmaceutical company’s stock valued at $341,796,000 after acquiring an additional 588,000 shares during the period. Finally, Russell Investments Group Ltd. lifted its holdings in Celgene Corporation by 9.2% in the second quarter. Russell Investments Group Ltd. now owns 641,697 shares of the biopharmaceutical company’s stock valued at $83,344,000 after acquiring an additional 54,210 shares during the period. 79.24% of the stock is owned by institutional investors.

In other Celgene Corporation news, Director Michael D. Casey sold 9,250 shares of the company’s stock in a transaction dated Tuesday, September 5th. The stock was sold at an average price of $139.03, for a total value of $1,286,027.50. Following the transaction, the director now directly owns 9,250 shares of the company’s stock, valued at approximately $1,286,027.50. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, Director Ernest Mario sold 18,506 shares of the company’s stock in a transaction dated Thursday, August 10th. The stock was sold at an average price of $130.52, for a total value of $2,415,403.12. Following the completion of the transaction, the director now directly owns 69,424 shares in the company, valued at $9,061,220.48. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 46,233 shares of company stock worth $6,268,259. Insiders own 0.95% of the company’s stock.

A number of research analysts have recently weighed in on CELG shares. BTIG Research cut Celgene Corporation from a “buy” rating to a “neutral” rating and raised their price target for the company from $96.93 to $131.70 in a research report on Friday, June 30th. Vetr upgraded Celgene Corporation from a “buy” rating to a “strong-buy” rating and set a $148.32 price target for the company in a research report on Thursday, August 10th. Jefferies Group LLC restated a “buy” rating and issued a $160.00 price target on shares of Celgene Corporation in a research report on Monday. Cantor Fitzgerald set a $162.00 price target on Celgene Corporation and gave the company a “buy” rating in a research report on Monday. Finally, SunTrust Banks, Inc. set a $150.00 price target on Celgene Corporation and gave the company a “buy” rating in a research report on Thursday, July 6th. Two research analysts have rated the stock with a sell rating, five have assigned a hold rating and twenty-two have issued a buy rating to the stock. The stock currently has a consensus rating of “Buy” and a consensus price target of $150.80.

Celgene Corporation (CELG) opened at 136.71 on Tuesday. Celgene Corporation has a 1-year low of $96.93 and a 1-year high of $147.17. The firm has a market capitalization of $106.96 billion, a price-to-earnings ratio of 42.34 and a beta of 1.89. The stock has a 50 day moving average price of $141.03 and a 200 day moving average price of $130.15.

Celgene Corporation (NASDAQ:CELG) last issued its earnings results on Thursday, July 27th. The biopharmaceutical company reported $1.82 earnings per share for the quarter, topping the consensus estimate of $1.61 by $0.21. Celgene Corporation had a return on equity of 68.51% and a net margin of 21.35%. The company had revenue of $3.27 billion for the quarter, compared to analyst estimates of $3.23 billion. During the same period in the prior year, the firm posted $1.44 EPS. The business’s revenue was up 18.7% compared to the same quarter last year. Analysts predict that Celgene Corporation will post $7.33 EPS for the current year.

ILLEGAL ACTIVITY NOTICE: This report was posted by Watch List News and is the sole property of of Watch List News. If you are accessing this report on another site, it was illegally stolen and republished in violation of United States and international trademark and copyright laws. The legal version of this report can be viewed at https://www.watchlistnews.com/horan-capital-advisors-llc-has-3-64-million-holdings-in-celgene-corporation-celg/1635654.html.

About Celgene Corporation

Celgene Corporation is an integrated global biopharmaceutical company. The Company, together with its subsidiaries, is engaged in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases through solutions in protein homeostasis, immuno-oncology, epigenetics, immunology and neuro-inflammation.

Want to see what other hedge funds are holding CELG? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Celgene Corporation (NASDAQ:CELG).

Institutional Ownership by Quarter for Celgene Corporation (NASDAQ:CELG)

Receive News & Ratings for Celgene Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celgene Corporation and related companies with Analyst Ratings Network's FREE daily email newsletter.